First Time Loading...

Sutro Biopharma Inc
NASDAQ:STRO

Watchlist Manager
Sutro Biopharma Inc Logo
Sutro Biopharma Inc
NASDAQ:STRO
Watchlist
Price: 3.77 USD -0.79% Market Closed
Updated: Apr 19, 2024

Intrinsic Value

STRO's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Sutro Biopharma Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. [ Read More ]

The intrinsic value of one STRO stock under the Base Case scenario is 8.2 USD. Compared to the current market price of 3.77 USD, Sutro Biopharma Inc is Undervalued by 54%.

Key Points:
STRO Intrinsic Value
Base Case
8.2 USD
Undervaluation 54%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Sutro Biopharma Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling STRO stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Sutro Biopharma Inc

Provide an overview of the primary business activities
of Sutro Biopharma Inc.

What unique competitive advantages
does Sutro Biopharma Inc hold over its rivals?

What risks and challenges
does Sutro Biopharma Inc face in the near future?

Has there been any significant insider trading activity
in Sutro Biopharma Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Sutro Biopharma Inc.

Provide P/S
for Sutro Biopharma Inc.

Provide P/E
for Sutro Biopharma Inc.

Provide P/OCF
for Sutro Biopharma Inc.

Provide P/FCFE
for Sutro Biopharma Inc.

Provide P/B
for Sutro Biopharma Inc.

Provide EV/S
for Sutro Biopharma Inc.

Provide EV/GP
for Sutro Biopharma Inc.

Provide EV/EBITDA
for Sutro Biopharma Inc.

Provide EV/EBIT
for Sutro Biopharma Inc.

Provide EV/OCF
for Sutro Biopharma Inc.

Provide EV/FCFF
for Sutro Biopharma Inc.

Provide EV/IC
for Sutro Biopharma Inc.

Show me price targets
for Sutro Biopharma Inc made by professional analysts.

What are the Revenue projections
for Sutro Biopharma Inc?

How accurate were the past Revenue estimates
for Sutro Biopharma Inc?

What are the Net Income projections
for Sutro Biopharma Inc?

How accurate were the past Net Income estimates
for Sutro Biopharma Inc?

What are the EPS projections
for Sutro Biopharma Inc?

How accurate were the past EPS estimates
for Sutro Biopharma Inc?

What are the EBIT projections
for Sutro Biopharma Inc?

How accurate were the past EBIT estimates
for Sutro Biopharma Inc?

Compare the revenue forecasts
for Sutro Biopharma Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Sutro Biopharma Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Sutro Biopharma Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Sutro Biopharma Inc compared to its peers.

Compare the P/E ratios
of Sutro Biopharma Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Sutro Biopharma Inc with its peers.

Analyze the financial leverage
of Sutro Biopharma Inc compared to its main competitors.

Show all profitability ratios
for Sutro Biopharma Inc.

Provide ROE
for Sutro Biopharma Inc.

Provide ROA
for Sutro Biopharma Inc.

Provide ROIC
for Sutro Biopharma Inc.

Provide ROCE
for Sutro Biopharma Inc.

Provide Gross Margin
for Sutro Biopharma Inc.

Provide Operating Margin
for Sutro Biopharma Inc.

Provide Net Margin
for Sutro Biopharma Inc.

Provide FCF Margin
for Sutro Biopharma Inc.

Show all solvency ratios
for Sutro Biopharma Inc.

Provide D/E Ratio
for Sutro Biopharma Inc.

Provide D/A Ratio
for Sutro Biopharma Inc.

Provide Interest Coverage Ratio
for Sutro Biopharma Inc.

Provide Altman Z-Score Ratio
for Sutro Biopharma Inc.

Provide Quick Ratio
for Sutro Biopharma Inc.

Provide Current Ratio
for Sutro Biopharma Inc.

Provide Cash Ratio
for Sutro Biopharma Inc.

What is the historical Revenue growth
over the last 5 years for Sutro Biopharma Inc?

What is the historical Net Income growth
over the last 5 years for Sutro Biopharma Inc?

What is the current Free Cash Flow
of Sutro Biopharma Inc?

Financials

Balance Sheet Decomposition
Sutro Biopharma Inc

Current Assets 421.5m
Cash & Short-Term Investments 375.6m
Receivables 36.1m
Other Current Assets 9.8m
Non-Current Assets 49.2m
PP&E 44.8m
Other Non-Current Assets 4.4m
Current Liabilities 93.7m
Accounts Payable 9.4m
Accrued Liabilities 59.6m
Other Current Liabilities 24.7m
Non-Current Liabilities 227.3m
Other Non-Current Liabilities 227.3m
Efficiency

Earnings Waterfall
Sutro Biopharma Inc

Revenue
153.7m USD
Operating Expenses
-243m USD
Operating Income
-89.3m USD
Other Expenses
-17.5m USD
Net Income
-106.8m USD

Free Cash Flow Analysis
Sutro Biopharma Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

STRO Profitability Score
Profitability Due Diligence

Sutro Biopharma Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional 1-Year Revenue Growth
Negative Revenue Growth Forecast
Declining ROE
20/100
Profitability
Score

Sutro Biopharma Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.

STRO Solvency Score
Solvency Due Diligence

Sutro Biopharma Inc's solvency score is 44/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Low Altman Z-Score
44/100
Solvency
Score

Sutro Biopharma Inc's solvency score is 44/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

STRO Price Targets Summary
Sutro Biopharma Inc

Wall Street analysts forecast STRO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for STRO is 13.15 USD with a low forecast of 8.08 USD and a high forecast of 21 USD.

Lowest
Price Target
8.08 USD
114% Upside
Average
Price Target
13.15 USD
249% Upside
Highest
Price Target
21 USD
457% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

STRO Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

STRO Price
Sutro Biopharma Inc

1M 1M
+6%
6M 6M
+15%
1Y 1Y
-22%
3Y 3Y
-80%
5Y 5Y
-62%
10Y 10Y
-75%
Annual Price Range
3.77
52w Low
2.07
52w High
5.88
Price Metrics
Average Annual Return 5.06%
Standard Deviation of Annual Returns 53.57%
Max Drawdown -92%
Shares Statistics
Market Capitalization 290m USD
Shares Outstanding 76 920 704
Percentage of Shares Shorted 3.91%

STRO Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Sutro Biopharma Inc Logo
Sutro Biopharma Inc

Country

United States of America

Industry

Biotechnology

Market Cap

290m USD

Dividend Yield

0%

Description

Sutro Biopharma Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. The company is headquartered in South San Francisco, California and currently employs 224 full-time employees. The company went IPO on 2018-09-27. The company is focused on deploying its integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF, to create a variety of protein therapeutics, initially for cancer. The company is engaged in designing therapeutics using potent modalities, including cytokine-based therapeutics, immuno-oncology agents, antibody-drug conjugates (ADCs) and bispecific antibodies that are directed against clinically validated targets. Its product candidate includes STRO-002 and STRO-001. STRO-002, is an ADC directed against folate receptor-alpha, for patients with FolRα-expressing cancers, such as ovarian and endometrial cancers. STRO-001, is an ADC directed against CD74, for patients with B-cell malignancies, such as multiple myeloma and non-Hodgkin lymphoma. Its product candidates are designed and optimized for therapeutic index by placing linker-warheads at specific locations within the antibody.

Contact

CALIFORNIA
South San Francisco
111 Oyster Point Blvd.
+16503928412.0
http://www.sutrobio.com/

IPO

2018-09-27

Employees

224

Officers

CEO & Director
Mr. William J. Newell J.D.
President & COO
Ms. Jane Chung R.Ph.
Founder
Dr. James R. Swartz DSc, Ph.D., Sc.D.
CFO & Secretary
Mr. Edward C. Albini M.B.A
Chief Technical Operations Officer
Dr. Venkatesh Srinivasan Ph.d.
Chief Scientific Officer
Dr. Hans-Peter Gerber Ph.D.
Show More
General Counsel
Mr. David Pauling J.D., M.A.
Chief People & Communications Officer
Ms. Linda A. Fitzpatrick
Chief Portfolio Strategy & Alliance Officer
Dr. Nicki Vasquez Ph.D.
Chief Medical Officer
Dr. Anne Elizabeth Borgman-Hagey M.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one STRO stock?

The intrinsic value of one STRO stock under the Base Case scenario is 8.2 USD.

Is STRO stock undervalued or overvalued?

Compared to the current market price of 3.77 USD, Sutro Biopharma Inc is Undervalued by 54%.